Aktie VERSEON CORP
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Verseon Corp London S.E.

Aktien

USU9221J1098

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Verseon Gains US Patent Protection for Compounds That Could Eliminate Bleeding Risks of Current Anticoagulants
Verseon Corporation Reports Earnings Results for the Half Year Ended June 30, 2019
Verseon Corporation Reports Earnings Results for the Full Year Ended December 31, 2018
Verseon Corporation Auditor Raises 'Going Concern' Doubt
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs
Verseon Corporation Presents Preclinical Efficacy Data for the First Development Candidate for Clinical Trials in Their Diabetic Eye Disease Program at ARVO 2019
Verseon Corporation announced that it has received $0.1014 million in funding
Verseon Corporation will Change its Ticker to VERS from VSN
Verseon Corporation announced that it expects to receive $0.1014 million in funding
Verseon Corporation Announces First Participants Receive Verseon PRrecision Oral AntiCoagulant in Phase I Trial
Verseon Corporation Announces Resignation of Xavier Rolet as Non-Executive Director
Verseon Corporation Announces Board Changes
Verseon Corporation Unveils Transformative Blockchain Technology for Tokenized Securities
Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-1902
Verseon Corporation Provides Interim Report Charts Progress of Development Programs as it Submits Phase I Protocol for Precision Anticoagulant
Verseon Corporation Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018
Verseon Corporation Submits Phase I Protocol for VE-1902
Verseon Corporation Announces Consolidated Earnings Results for the Year Ended December 31, 2018
Verseon Preparing for Anticoagulant Phase I Trial
Verseon Presents New Preclinical Data on Its Novel Class of Precision Oral Anticoagulants
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Aktie
  5. Nachrichten Verseon Corp
  6. Andere Sprachen